SADEL project aims at developing the first generation of non-parenteral biotherapeutics tackling disease targets in digestive track by using innovative high-affinity protein scaffolds.

SADEL consortium is assembled as a virtual biopharmaceutical company with SMEs, academics, clinicians and pharma industry with all cutting-edge skills: production (including GMP), analytics, formulation, preclinical and clinical development, up to licensing.